Skip to main content

Table 2 Results of univariate and multivariate logistic regression analyses for polypharmacy

From: Number of consulting medical institutions and risk of polypharmacy in community-dwelling older people under a healthcare system with free access: a cross-sectional study in Japan

 Unadjusted OR (95% CI)Adjusted OR (95% CI)
The number of consulting medical institutions
 11 (reference)1 (reference)
 21.85 (1.23–2.79)1.50 (0.94–2.37)
 ≥35.06 (3.23–7.92)3.34 (1.98–5.65)
Age (every 1 year old increase) 1.07 (1.04–1.10)1.07 (1.03–1.10)
Sex
 Women1 (reference)1 (reference)
 Men1.81 (1.27–2.59)1.98 (1.26–3.10)
Household economya
 Very poor1.94 (1.02–3.69)1.53 (0.72–3.26)
 Poor1.56 (1.03–2.34)1.50 (0.95–2.38)
 Normal1 (reference)1 (reference)
 Richb0.66 (0.31–1.42)0.73 (0.32–1.66)
 Very richb
Comorbidities
 Hypertension1.21 (0.86–1.72) 
 Stroke1.20 (0.49–2.96) 
 Heart disease3.81 (2.53–5.74)2.89 (1.75–4.76)
 Diabetes mellitus2.49 (1.69–3.67)2.49 (1.54–4.02)
 Dyslipidemia1.20 (0.77–1.88) 
 Respiratory disorder1.79 (0.97–3.29) 
 Gastrointestinal disorder2.35 (1.42–3.91)1.71 (0.92–3.19)
 Renal urologic disorder2.25 (1.41–3.59)1.04 (0.56–1.92)
 Musculoskeletal disorder2.35 (1.47–3.76)2.44 (1.34–4.47)
 Injury2.19 (0.84–5.74) 
 Malignancy1.80 (0.92–3.54) 
 Hematologic disease1.55 (0.50–4.76) 
 Depression2.03 (0.53–7.74) 
 Dementia3.12 (0.90–10.79) 
 Parkinson’s diseaseNot available 
 Ear disorder1.08 (0.52–2.25) 
 Other1.08 (0.63–1.85) 
The number of comorbidities
  11 (reference)1 (reference)
  22.41 (1.51–3.85)1.52 (0.90–2.55)
  34.28 (2.51–7.29)1.58 (0.83–2.99)
  49.31 (5.09–17.04)2.59 (1.24–5.44)
 ≥517.30 (6.78–44.09)2.24 (0.68–7.43)
  1. CI confidence interval, OR odds ratio
  2. a25 people with missing data were not included in the multivariate logistic regression analyses
  3. bPeople in the rich and very rich categories were grouped because of the small number of participants